Bivalirudin: a review of its potential place in the management of acute coronary syndromes

Drugs
Christopher I Carswell, Greg L Plosker

Abstract

Bivalirudin, a synthetic analogue of hirudin, is a specific and reversible inhibitor of thrombin which binds directly with both fluid-phase and clot-bound thrombin. In patients with unstable angina undergoing percutaneous transluminal coronary angioplasty (PTCA), results from a large well designed study and its reanalysis (n = 4312) indicate that bivalirudin is more effective than heparin in the prevention of ischaemic complications for up to 90 days after the start of treatment. In addition, among patients undergoing PTCA for post myocardial infarction (MI) bivalirudin may be more effective than heparin in preventing ischaemic complications for up to 180 days after treatment was started. Data from dose-finding studies indicate bivalirudin has potential in the treatment of patients with unstable angina not undergoing percutaneous coronary intervention (PCI); however, well designed comparative studies are needed before firm conclusions can be made. Among patients with acute ST elevation MI, randomised trials have demonstrated bivalirudin to be significantly more effective than heparin in improving early patency in patients receiving thrombolytic therapy with streptokinase. Data from the Hirulog and Early Reperfusion/Occlusion (H...Continue Reading

References

Apr 1, 1992·Journal of the American College of Cardiology·A M LincoffE J Topol
Jul 16, 1992·The New England Journal of Medicine·P ThérouxJ McCans
Oct 29, 1991·Biochemistry·E W DavieW Kisiel
Oct 27, 1988·The New England Journal of Medicine·P ThérouxP deGuise
Nov 28, 1985·The New England Journal of Medicine·J A CairnsM G Myers
Jun 1, 1995·Drugs·M Verstraete, P Zoldhelyi
Dec 13, 1994·Biochemistry·M A ParryS R Stone
Sep 2, 1993·The New England Journal of Medicine·UNKNOWN GUSTO investigators
Apr 1, 1993·The American Journal of Cardiology·C P CannonE Braunwald
Jan 1, 1996·The Journal of Surgical Research·M R JacksonB M Alving
Jun 12, 1997·The New England Journal of Medicine·UNKNOWN EPILOG Investigators
Nov 14, 1997·Journal of the American College of Cardiology·P B ShahJ A Bittl
Sep 2, 1998·The American Journal of Cardiology·J E BurchenalJ A Bittl
Sep 24, 1999·European Heart Journal·F J Van de Werf
Nov 16, 1999·Circulation·D F KongR M Califf
Nov 4, 2000·Expert Opinion on Investigational Drugs·R Scatena
Sep 1, 2001·Lancet·UNKNOWN Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators

❮ Previous
Next ❯

Citations

Sep 6, 2002·Nature·Edward Tuddenham
Dec 20, 2003·Neurosurgery·Mark R HarriganL Nelson Hopkins
Jun 13, 2003·Current Cardiology Reports·Debabrata Mukherjee, Kim A Eagle
Dec 14, 2004·Drugs·Jack Ansell, David Bergqvist
Jul 13, 2004·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Karl-Georg Fischer
May 17, 2007·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Vijay S Ramanath, Kim A Eagle
Mar 20, 2020·Minerva anestesiologica·Gennaro ScibelliGennaro Savoia
Apr 15, 2006·Cardiovascular Drug Reviews·Nicolas W Shammas
Jul 25, 2021·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Giulia MazzoccantiFrancesco Gasparrini

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.